Capmatinib
- CAS No.
- 1029712-80-8
- Chemical Name:
- Capmatinib
- Synonyms
- INC280;INCB28060;INC28060;2-Fluoro-N-Methyl-4-(7-quinolin-6-ylMethyl-iMidazo[1,2-b][1,2,4] triazin-2-yl)-benzaMide;NC280;CS-192;INCB028060;NVP-INC280;CapMatinib;Karma for,
- CBNumber:
- CB92574678
- Molecular Formula:
- C23H17FN6O
- Molecular Weight:
- 412.42
- MDL Number:
- MFCD18633285
- MOL File:
- 1029712-80-8.mol
- MSDS File:
- SDS
| Melting point | >250°C (dec.) |
|---|---|
| Density | 1.40 |
| vapor pressure | 0-0Pa at 20-25℃ |
| storage temp. | -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 13.82±0.46(Predicted) |
| form | Solid |
| color | Pale Yellow to Light Yellow |
| InChI | InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31) |
| InChIKey | LIOLIMKSCNQPLV-UHFFFAOYSA-N |
| SMILES | C(NC)(=O)C1=CC=C(C2=NN3C(CC4=CC=C5C(=C4)C=CC=N5)=CN=C3N=C2)C=C1F |
| LogP | 1.6-2.2 at 35℃ and pH7-9 |
| FDA UNII | TY34L4F9OZ |
| ATC code | L01EX17 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
Capmatinib price More Price(28)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 20056 | INCB 28060 ≥98% | 1029712-80-8 | 5mg | $88 | 2024-03-01 | Buy |
| Cayman Chemical | 20056 | INCB 28060 ≥98% | 1029712-80-8 | 10mg | $157 | 2024-03-01 | Buy |
| Cayman Chemical | 20056 | INCB 28060 ≥98% | 1029712-80-8 | 50mg | $647 | 2024-03-01 | Buy |
| Biosynth Carbosynth | FF40658 | Capmatinib | 1029712-80-8 | 500mg | $800 | 2021-12-16 | Buy |
| ChemScene | CS-1541 | Capmatinib 99.92% | 1029712-80-8 | 200mg | $190 | 2021-12-16 | Buy |
Capmatinib Chemical Properties,Uses,Production
MET small molecule inhibitor
Capmatinib(Synonyms: INC280; INCB28060) is a competitive inhibitor with very potent and selective activity against MET compared to other kinases. It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day. Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels.
Originator
Novartis
Description
INCB 28060 is an inhibitor of heptatocyte growth factor receptor (HGFR, also known as c-Met), potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM). It blocks cell proliferation and migration or induces apoptosis in different types of cancer cells. INCB 28060 is orally bioavailable and inhibits the growth of HGFR-dependent tumors in mice. It also improves efficacy of gemcitabine in a mouse pancreatic cancer model and reduces migration and adhesion in ovarian cancer cell models.
Description
Capmatinib is a competitive inhibitor with very potent and selective activity against MET compared to other kinases.
Uses
2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide is used in the preparation of a combination formulation with allosteric SHP2 inhibitor TNO155. Used in treatment of non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
Side effects
Most common adverse events were nausea, peripheral edema, decreased appetite, rash, and increased amylase and lipase levels.
in vitro
It has been shown in vitro that cell lines made resistant to erlotinib, an EGFR inhibitor, could be resensitized after capmatinib treatment. Results from a phase Ib/II study of patients with EGFR-mutated, MET-dysregulated NSCLC have shown promising responses to a combination of capmatinib and gefitinib (EGFR TKI) following disease progression from an only EGFR TKI treatment regimen. Recommended phase II dose was determined to be capmatinib 400 mg twice/day and gefitinib 250 mg once/day.
target
c-MET
References
1. liu x, wang q, yang g, et al. a novel kinase inhibitor, incb28060, blocks c-met-dependent signaling, neoplastic activities, and cross-talk with egfr and her-3. clinical cancer research : an official journal of the american association for cancer research. 2011;17(22):7127-7138.
Capmatinib Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 | admin@ahdchem.com | China | 298 | 58 |
| Zison Pharmaceutical (Shandong) Co., Ltd. | +86-0086-531-88259693 +86-18660188356 | maguanglei@zisonpharm.com | China | 53 | 58 |
| shandong perfect biotechnology co.ltd | +86-53169958659; +8618596095638 | sales@sdperfect.com | China | 294 | 58 |
| Nanjing Gold Pharmaceutical Technology Co. Ltd. | 025-84209270 15906146951 | CHINA | 115 | 55 | |
| Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 | fandachem@gmail.com | China | 9348 | 55 |
| Nanjing Finetech Chemical Co., Ltd. | 025-85710122 17714198479 | sales@fine-chemtech.com | CHINA | 885 | 55 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 32480 | 60 |
| Shanghai Arbor Chemical Co., Ltd. | 021-60451682 | act@arborchemical.com | CHINA | 906 | 58 |
| TianYuan Pharmaceutical CO.,LTD | +86-755-23284190 13684996853 | sales@tianpharm.com | CHINA | 304 | 58 |
| Hubei xin bonus chemical co. LTD | 86-13657291602 | linda@hubeijusheng.com | CHINA | 22968 | 58 |
Related articles
- Capmatinib: Pharmacodynamics, Pharmacokinetics and Adverse Events
- Capmatinib targets MET exon 14 skipping mutations, inhibiting proliferation and migration in non-small cell lung cancer. It ha....
- Mar 1，2024
- Can Capmatinib treat non-small cell lung cancer (NSCLC) in adults ?
- Capmatinib is an FDA-approved targeted drug for the treatment of adult patients with non-small cell lung cancer(NSCLC).
- Nov 8，2023
View Lastest Price from Capmatinib manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2024-03-12 | Capmatinib
1029712-80-8
|
US $0.00 / g | 1g | 98% HPLC | 1KG | shandong perfect biotechnology co.ltd | |
 |
2023-12-21 | Capmatinib
1029712-80-8
|
US $0.00-0.00 / kg | 1kg | 99%，single impurity＜0.1 | 1 ton | Nanjing Fred Technology Co., Ltd | |
 |
2023-12-01 | Capmatinib
1029712-80-8
|
US $0.00-0.00 / kg | 1kg | ＞99% by HPLC | 10kg/month | Zison Pharmaceutical (Shandong) Co., Ltd. |
-
- Capmatinib
1029712-80-8
- US $0.00 / g
- 98% HPLC
- shandong perfect biotechnology co.ltd
-
- Capmatinib
1029712-80-8
- US $0.00-0.00 / kg
- 99%，single impurity＜0.1
- Nanjing Fred Technology Co., Ltd
-
- Capmatinib
1029712-80-8
- US $0.00-0.00 / kg
- ＞99% by HPLC
- Zison Pharmaceutical (Shandong) Co., Ltd.